Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C43H58N4O12 |
Molecular Weight | 822.9402 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(\C=N\N5CCN(C)CC5)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C4C(O)=C3C
InChI
InChIKey=JQXXHWHPUNPDRT-WLSIYKJHSA-N
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
Molecular Formula | C43H58N4O12 |
Molecular Weight | 822.9402 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rxlist.com/rifadin-drug.htm
http://www.wikidoc.org/index.php/Rifampin_(oral)
Curator's Comment: description was created based on several sources, including:
http://www.rxlist.com/rifadin-drug.htm
http://www.wikidoc.org/index.php/Rifampin_(oral)
Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. It is FDA approved for the treatment of tuberculosis, meningococcal carrier state. Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. Common adverse reactions include heartburn, epigastric distress, anorexia, nausea, vomiting, jaundice, flatulence, cramps.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P0A8V2 Gene ID: 948488.0 Gene Symbol: rpoB Target Organism: Escherichia coli (strain K12) |
|||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176562 |
18.5 µM [Ki] | ||
Target ID: CHEMBL3721 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176562 |
30.2 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RIFADIN Approved UseIn the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. Tuberculosis Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. RIFADIN IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. Meningococcal Carriers Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (See WARNINGS.) Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.3632001E10 |
|||
Curative | RIFADIN Approved UseIn the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. Tuberculosis Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. RIFADIN IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. Meningococcal Carriers Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (See WARNINGS.) Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.3632001E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.6 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
20 mg/kg 1 times / day steady-state, oral dose: 20 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
25.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
25 mg/kg 1 times / day steady-state, oral dose: 25 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
33.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
30 mg/kg 1 times / day steady-state, oral dose: 30 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
35.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
35 mg/kg 1 times / day steady-state, oral dose: 35 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
10 mg/kg 1 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22330931/ |
10 mg/kg 1 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22330931/ |
10 mg/kg 1 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
325 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9773393/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIFAMPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
113 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
20 mg/kg 1 times / day steady-state, oral dose: 20 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
135 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
25 mg/kg 1 times / day steady-state, oral dose: 25 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
190 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
30 mg/kg 1 times / day steady-state, oral dose: 30 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
235 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
35 mg/kg 1 times / day steady-state, oral dose: 35 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25654354/ |
10 mg/kg 1 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: ISONIAZID |
RIFAMPIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9773393/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
25-DESACETYLRIFAMPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
16.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9773393/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIFAMPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
60 g single, oral (total) Overdose |
unknown, 26 years n = 1 Health Status: unknown Age Group: 26 years Sex: M Population Size: 1 Sources: |
Other AEs: Pruritus... |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, adult n = 8 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: adult Population Size: 8 Sources: |
|
1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
unknown, adult n = 18 Health Status: unknown Age Group: adult Sex: M Population Size: 18 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pruritus | grade 5, 1 patient | 60 g single, oral (total) Overdose |
unknown, 26 years n = 1 Health Status: unknown Age Group: 26 years Sex: M Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
no | |||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
no | |||
yes [IC50 79.1 uM] | ||||
yes [Ki 18.5 uM] | ||||
yes [Ki 30.2 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12584154/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/30170758/ |
yes | |||
yes | yes (co-administration study) Comment: induced levels of CYP1C19 apoprotein to 330% of control; coadministration with simvastatin: decrease exposure of simvastatin; coadministration with irinotecan: decrease irinotecan and active metabolite exposure; rifampicin reduced AUC of repaglinide by 57%; Page: 12.0 |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/30170758/ |
yes | yes (co-administration study) Comment: Coadministration of ertugliflozin with rifampin decreased ertugliflozin AUC0-∞ and Cmax by 39% and 15%, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/30170758/ |
PubMed
Title | Date | PubMed |
---|---|---|
[Side effects of rifampicin in the treatment of chronic pulmonary tuberculosis by the intermittent method]. | 1975 Mar 31 |
|
[A new case of acute renal failure, with high hemolysis, after rifampicin (author's transl)]. | 1975 Nov-Dec |
|
[Tolerance of rifampicin in long-term treatment of patients with pulmonary tuberculosis]. | 1976 Feb |
|
Antituberculosis activity of certain antifungal and antihelmintic drugs. | 1999 |
|
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 Dec |
|
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. | 1999 Sep |
|
Antimycobacterial activities of novel levofloxacin analogues. | 2000 Aug |
|
Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. | 2000 Feb |
|
Minimal change nephrotic syndrome associated with rifampicin treatment. | 2000 Jul |
|
Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. | 2000 Jul |
|
Activity of poloxamer CRL-1072 against drug-sensitive and resistant strains of Mycobacterium tuberculosis in macrophages and in mice. | 2000 Jun |
|
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. | 2000 Jun |
|
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. | 2000 Oct |
|
Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. | 2000 Sep |
|
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. | 2000 Sep |
|
Rifampicin-induced erythema nodosum leprosum-like eruption in borderline lepromatous leprosy. | 2001 Apr-Jun |
|
Drug-induced acute interstitial nephritis. | 2001 Aug |
|
Postantibiotic effects of antituberculosis agents alone and in combination. | 2001 Dec |
|
[Clinico-pathological features and possible pathogenesis of rifampicin-induced acute renal failure]. | 2001 Jun |
|
Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. | 2001 Jun |
|
CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. | 2001 May |
|
[Acute renal insufficiency and interstitial nephritis caused by rifampicin. A comment on this subject]. | 2001 May-Jun |
|
Acute renal failure caused by rifampicin re-exposure with 10-year of interval. | 2001 Nov |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Antimycobacterial plant terpenoids. | 2001 Nov |
|
Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. | 2001 Oct |
|
Acute renal failure complicating rifampicin therapy. | 2001 Sep |
|
Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. | 2002 Jan |
|
Rapidly progressive glomerulonephritis due to rifampicin therapy. | 2002 Jan |
|
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. | 2002 Jan |
|
[Specific features of acute renal failure in patients treated with rifampicin]. | 2002 Jan-Mar |
|
Functional analysis of the rat bile salt export pump gene promoter. | 2002 Jul |
|
Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. | 2002 May |
|
3-[4'-bromo-(1,1'-biphenyl)-4-yl]-N, N-dimethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities. | 2002 Nov |
|
Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. | 2002 Oct 15 |
|
Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. | 2003 Apr |
|
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. | 2003 Apr |
|
A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. | 2003 Apr 18 |
|
Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. | 2003 Jan |
|
Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. | 2003 Mar |
|
Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. | 2003 May |
|
Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. | 2003 May |
Patents
Sample Use Guides
Tuberculosis: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or intravenous. It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
Meningococcal Carriers: it is recommended that 600 mg rifampin be administered twice daily for two days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11020254
By the absolute concentration method, the MIC50 and MIC90 of rifampicin were 0.5-1 mg/L
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 21:22:23 UTC 2023
by
admin
on
Thu Jul 06 21:22:23 UTC 2023
|
Record UNII |
VJT6J7R4TR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
6585
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ETH/ISO/PYR/RIF)
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NDF-RT |
N0000175500
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ISO/RIF)
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ISO/PYR/RIF)
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
FDA ORPHAN DRUG |
7685
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.3
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NDF-RT |
N0000007911
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NDF-RT |
N0000007911
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-VATC |
QJ04AM05
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ATC |
J04AB02
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ATC |
J04AM07
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ATC |
J04AM02
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ATC |
J04AM05
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NCI_THESAURUS |
C280
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
FDA ORPHAN DRUG |
928022
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-VATC |
QJ04AB02
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NDF-RT |
N0000007911
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-VATC |
QJ04AM02
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ATC |
J04AM06
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ETH/ISO/RIF)
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-VATC |
QJ04AM06
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NDF-RT |
N0000007911
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
NCI_THESAURUS |
C25995
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
WHO-VATC |
QJ54AB02
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
||
|
LIVERTOX |
NBK548314
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
28077
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
71365
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
CHEMBL374478
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
RIFAMPICIN
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
RIFAMPIN
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | Description: A brick red to red-brown, crystalline powder. Solubility: Very slightly to slightly soluble in water; soluble in methanol R; slightly soluble in acetone R, ethanol (~750 g/l) TS, and ether R. Category: Antileprosy drug; antituberculosis drug. Storage: Rifampicin should be kept in a tightly closed container or in an atmosphere of nitrogen, protected from light. Additional information: Rifampicin exhibits polymorphism. Definition: Rifampicin contains not less than 97.0% and not more than 102.0% of C43H58N4O12, calculated with reference to the dried substance. | ||
|
100000080561
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
VJT6J7R4TR
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
DTXSID6021244
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
9384
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | RxNorm | ||
|
2323
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
3181
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
135398735
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
Rifampin
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
1604009
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
845504-52-1
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
ALTERNATIVE | |||
|
D012293
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
2765
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
236-312-0
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
C811
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
SUB10309MIG
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
M9611
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | Merck Index | ||
|
2377
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
DB01045
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
13292-46-1
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
113926
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY | |||
|
VJT6J7R4TR
Created by
admin on Thu Jul 06 21:22:26 UTC 2023 , Edited by admin on Thu Jul 06 21:22:26 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR |
CAN BE USED FOR IN-VIVO STUDIES OF TRANSPORTER
IN-VIVO
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INDUCER |
POTENT
|
||
|
METABOLIC ENZYME -> INDUCER |
POTENT
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR |
SUBSTRATE USED: Bromsulphthalein (BSP)
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Duration of Action | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: END-STAGE RENAL DISEASE |
|
||
Tmax | PHARMACOKINETIC |
|
POPULATION: PEDIATRICS |
|
||
Cmax | PHARMACOKINETIC |
|
POPULATION: PEDIATRICS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: HEPATIC IMPAIRMENT |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: IV |
|
||
Cmax | PHARMACOKINETIC |
|
POPULATION: PEDIATRICS |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: N. MENINGIDITIS |
|
||
Tmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: N. MENINGIDITIS |
|
||